Use of methotrexate in patients with psoriatic arthritis

被引：0

作者：

Ceponis, A. ^{[1
]}

Kavanaugh, A. ^{[1
]}

机构：

[1] Univ Calif San Diego, Ctr Innovat Therapy, Div Rheumatol Allergy & Immunol, La Jolla, CA 92037 USA

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2010年 / 28卷 / 05期

关键词：

Methotrexate; psoriatic arthritis; disease modifying drugs; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; SYNOVIAL MEMBRANES; THERAPY; TRIAL; LIVER; LEFLUNOMIDE; DISEASE; RATES;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite a paucity of high quality clinical data, methotrexate (MTX) remains one of the most commonly used medications in the treatment of patients with psoriatic arthritis (PsA). This report addresses mechanistic rationale, available clinical evidence, safety considerations, and a potential research agenda regarding the use of MTX in the management of PsA.

引用

页码：S132 / S137

页数：6

共 43 条

[1]

ABUSHAKRA M, 1995, J RHEUMATOL, V22, P241

[2] Psoriatic arthritis, methotrexate, and liver toxicity [J].